JP2005519917A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519917A5
JP2005519917A5 JP2003563495A JP2003563495A JP2005519917A5 JP 2005519917 A5 JP2005519917 A5 JP 2005519917A5 JP 2003563495 A JP2003563495 A JP 2003563495A JP 2003563495 A JP2003563495 A JP 2003563495A JP 2005519917 A5 JP2005519917 A5 JP 2005519917A5
Authority
JP
Japan
Prior art keywords
cartilage
delivery system
targeted
drug delivery
targeted drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003563495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/003175 external-priority patent/WO2003063799A2/en
Publication of JP2005519917A publication Critical patent/JP2005519917A/ja
Publication of JP2005519917A5 publication Critical patent/JP2005519917A5/ja
Withdrawn legal-status Critical Current

Links

JP2003563495A 2002-02-01 2003-01-31 軟骨分解の全身阻害のための組成物および方法 Withdrawn JP2005519917A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35355202P 2002-02-01 2002-02-01
PCT/US2003/003175 WO2003063799A2 (en) 2002-02-01 2003-01-31 Compositions and methods for systemic inhibition of cartilage degradation

Publications (2)

Publication Number Publication Date
JP2005519917A JP2005519917A (ja) 2005-07-07
JP2005519917A5 true JP2005519917A5 (es) 2005-12-22

Family

ID=27663221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003563495A Withdrawn JP2005519917A (ja) 2002-02-01 2003-01-31 軟骨分解の全身阻害のための組成物および方法

Country Status (8)

Country Link
EP (1) EP1496835A4 (es)
JP (1) JP2005519917A (es)
KR (1) KR20040094413A (es)
CN (1) CN1697647A (es)
AU (1) AU2003212898B2 (es)
CA (1) CA2474645C (es)
MX (1) MXPA04007124A (es)
WO (1) WO2003063799A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
DE10304994A1 (de) * 2003-02-07 2004-09-02 Aventis Pharma Deutschland Gmbh Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose
CN1798769A (zh) 2003-05-12 2006-07-05 内蒂穆恩公司 抗masp-2抗体
JP2007517913A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ, インコーポレイテッド カルシトニン遺伝子関連ペプチドを投与することによって急性心筋梗塞を処置するための方法およびカルシトニン遺伝子関連ペプチドを含有する組成物
JP2007517912A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ, インコーポレイテッド 心脈管および腎臓の適応症のための制御放出cgrp送達組成物
ATE515268T1 (de) * 2004-05-25 2011-07-15 Stryker Corp Verwendung von op-1 zur behandlung von knorpeldefekten
AU2011265308B2 (en) * 2004-05-25 2014-06-26 Stryker Corporation Use of Morphogenic Proteins for Treating Cartilage Defects
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PT1753456T (pt) 2004-06-10 2016-11-04 Univ Leicester Métodos para tratar condições associadas com a ativação do complemento dependente de masp-2
CN101141948B (zh) * 2005-03-14 2011-08-24 佰威控股有限公司 药物递送组合物及相关方法
SI1940465T1 (sl) 2005-10-26 2012-10-30 Novartis Ag Nova uporaba protiteles proti IL-1 beta
ES2542511T3 (es) 2007-05-11 2015-08-06 Adynxx, Inc. Expresión génica y dolor
EP2259774B1 (en) 2008-02-27 2012-12-12 Biomet Biologics, LLC Methods and compositions for delivering interleukin-1 receptor antagonist
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
CA2772084C (en) 2009-08-27 2016-10-18 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
CN106390117A (zh) 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
MX355648B (es) 2011-04-08 2018-04-26 Univ Leicester El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PT2704743T (pt) 2011-05-04 2020-06-17 Omeros Corp Composições para inibir a ativação de complemento dependente de masp-2
CA2872901A1 (en) 2012-05-10 2013-11-14 Adynxx, Inc. Formulations for the delivery of active ingredients
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
BR112015024758A2 (pt) * 2013-03-29 2017-10-24 Merrimack Pharmaceuticals Inc proteínas de fusão de ligação à cartilagem
IL283373B1 (en) 2013-10-17 2024-04-01 Omeros Corp Pharmaceutical preparations containing MASP-2 suppressors to suppress MASP-2-dependent complement activation and related diseases
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
EP3626822A1 (en) 2014-08-15 2020-03-25 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
JP6508670B2 (ja) * 2014-12-26 2019-05-08 国立大学法人広島大学 軟骨変性抑制剤
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
CN117398458A (zh) 2015-11-09 2024-01-16 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
CN106390099A (zh) * 2016-11-07 2017-02-15 广州赛莱拉干细胞科技股份有限公司 一种牙髓干细胞组合物及其应用
TW202402809A (zh) 2017-08-15 2024-01-16 美商歐米諾斯公司 用於治療和/或預防與造血幹細胞移植有關的移植物抗宿主病和/或瀰漫性肺泡出血和/或靜脈閉塞性病的方法
CN112274646B (zh) * 2019-07-12 2023-06-02 北京茵诺医药科技有限公司 用于靶向活化cd44分子的双亲性蛋白质-高分子结合体递送系统、其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502854A (ja) * 1988-10-24 1992-05-28 カターソン,ブルース 変形性関節症の初期段階の診断、モニタリングならびに治療の方法および組成物
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
WO2001007067A2 (en) * 1999-07-21 2001-02-01 Omeros Medical Systems, Inc. Solutions and methods for inhibition of pain, inflammation and cartilage degradation
DE69937070D1 (de) * 1998-11-05 2007-10-18 Omeros Corp Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
EP1401818A2 (en) * 2001-05-30 2004-03-31 Targesome, Inc. Targeted multivalent macromolecules
US6998019B2 (en) * 2002-09-10 2006-02-14 Fibermark, Inc. Glazed paper webs

Similar Documents

Publication Publication Date Title
JP2005519917A5 (es)
CA2474645A1 (en) Compositions and methods for systemic inhibition of cartilage degradation
US7067144B2 (en) Compositions and methods for systemic inhibition of cartilage degradation
Luhmann et al. Bone targeting for the treatment of osteoporosis
Storgard et al. Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist
ES2308985T3 (es) Disoluciones y procedimientos para la inhibicion del dolor, inflamacion y degradacion del cartilago.
AU2003212898A1 (en) Compositions and methods for systemic inhibition of cartilage degradation
Roy et al. Molecular targets in arthritis and recent trends in nanotherapy
US11771744B2 (en) Compositions and methods for inhibiting the biological activity of soluble biomolecules
US9260707B2 (en) Compounds for inhibition of MMP13-substrate interactions and methods of use thereof to treat osteoarthritis and cartilage degeneration
Kou et al. Matrix metalloproteinase inspired therapeutic strategies for bone diseases
WO2019089506A1 (en) Heterotopic ossification and method of treatment
US11793857B2 (en) Hard tissue therapeutics
Homandberg et al. Extracellular matrix fragments as regulators of cartilage metabolism in health and disease
Fazal-Ur-Rehman et al. Kartogenin induced chondrogenesis of stem cells and cartilage repair
Homandberg et al. The Role of Extracellular Matrix Fragments in the Autocrine Regulation of Cartilage Metabolism